XML 93 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments Financial Instruments (Details Textual 2) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 1 Months Ended 9 Months Ended
Nov. 30, 2020
Sep. 30, 2020
Feb. 29, 2020
Sep. 30, 2021
Dec. 31, 2020
Sage Therapeutics Inc.          
Business Acquisition [Line Items]          
Global licensing collaboration agreement, amount, shares purchased (in shares) $ 650.0        
Global licensing collaboration agreement, shares, purchased (in shares) 6.2        
Global licensing collaboration agreement, purchase price per share (in usd per share) $ 104.14        
Dividend yield percentage       0.00%  
Sangamo Therapeutics, Inc. Agreement          
Business Acquisition [Line Items]          
Global licensing collaboration agreement, amount, shares purchased (in shares)     $ 225.0    
Global licensing collaboration agreement, shares, purchased (in shares)     24.0    
Global licensing collaboration agreement, shares purchased per share (in usd per share)     $ 9.21    
Denali Therapeutics          
Business Acquisition [Line Items]          
Global licensing collaboration agreement, amount, shares purchased (in shares)   $ 465.0      
Global licensing collaboration agreement, shares purchased per share (in usd per share)   $ 34.94      
Strategic Investments          
Business Acquisition [Line Items]          
Strategic investment portfolio       $ 1,222.3  
Other noncurrent assets | Strategic Investments          
Business Acquisition [Line Items]          
Strategic investment portfolio         $ 2,024.6
Denali Therapeutics          
Business Acquisition [Line Items]          
Investment in common stock, shares purchased   13.0      
Dividend yield percentage   0.00%      
Sangamo          
Business Acquisition [Line Items]          
Investment in common stock, shares purchased       12.0  
Dividend yield percentage     0.00%